Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic

被引：0

作者：

Liegeon, Geoffroy ^{[1
]}

Kaperak, Christopher ^{[1
]}

Friedman, Eleanor E. ^{[1
]}

Djuricich, Paul ^{[2
]}

Dawdani, Alicia ^{[1
]}

Stafford, Kane ^{[2
]}

Plotkin, Sophie ^{[1
]}

Schmitt, Jessica ^{[1
]}

Hazra, Aniruddha ^{[1
]}

Christopoulos, Katerina A. ^{[3
]}

Schneider, John A. ^{[1
]}

Mcnulty, Moira C. ^{[1
]}

机构：

[1] Univ Chicago, Dept Med, Chicago, IL USA

[2] Univ Chicago, Dept Pharm, Chicago, IL USA

[3] Univ Calif San Francisco, Div HIV ID & Global Med, San Francisco, CA USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2025年 / 12卷 / 03期

基金：

美国国家卫生研究院;

关键词：

cabotegravir; injectable; long-acting; people with HIV; rilpivirine; PROGRAM; CARE;

D O I：

10.1093/ofid/ofaf094

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We describe referrals and uptake of long-acting injectable cabotegravir/rilpivirine at an academic clinic in Chicago. In a pharmacy-led model, 118 (18%) people with HIV were referred and 78 (12%) initiated long-acting injectable cabotegravir/rilpivirine from 1 January 2021 to 31 May 2023. Implementation, especially for people with HIV who were not virally suppressed, requires further support for patients, providers, and clinic systems.

引用

页数：7

共 50 条

[31] The optimum implementation of long-acting injectable cabotegravir-rilpivirine in sub-Saharan Africa
Dawood, Halima
LANCET GLOBAL HEALTH, 2021, 9 (05): : E563 - E564
[32] Early implementation of long-acting injectable cabotegravir for HIV prevention in a safety net primary care centre in US South
Baker, D.
Collins, L.
Cantos, V.
Hollenberg, E.
Kaplan, A.
Cowan, T.
Garcia, J.
Lora, M.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27
[33] Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong
Chan, M. C. J.
Chik, S. H. T.
Lamb, S. S.
Choi, Y. C. C.
Lau, W. T. A.
Leung, C. S. E.
To, P. Y. L.
Lau, P. L. D.
Tsang, T. Y. O.
HIV MEDICINE, 2023, 24 : 155 - 156
[34] Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Orkin, Chloe O. C.
Arasteh, Keikawus A. K.
Hernandez-Mora, M. Gorgolas M. G. H. M.
Pokrovsky, Vadim P. V.
Overton, Edgar T. O. E. T.
Girard, Pierre-Marie G. P. M.
Oka, Shinichi O. S.
Walmsley, Sharon W. S.
Bettacchi, Chris B. C.
Brinson, Cynthia B. C.
Philibert, Patrick P. P.
Lombaard, Johan L. J.
Clair, Marty C. M.
Crauwels, Herta C. H.
Ford, Susan L. F. S. L.
Patel, Parul P. P.
Chounta, Vasiliki C. V.
D'Amico, Ronald D. R.
Vanveggel, Simon V. S.
Dorey, David D. D.
Cutrell, Amy C. A.
Griffith, Sandy G. S.
Margolis, David A. M. D. A.
Williams, Peter E. W. P. E.
Parys, Wim P. W.
Smith, Kimberly Y. S. K. Y.
Spreen, William R. S. W. R.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1124 - 1135
[35] A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
Bares, Sara H.
Scarsi, Kimberly K.
CURRENT OPINION IN HIV AND AIDS, 2022, 17 (01) : 22 - 31
[36] Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience
Castelli, Alessandro
Lanzafame, Massimiliano
Morra, Matteo
Bertoldi, Marco
Delama, Andrea
Fait, Daniela
Vento, Sandro
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2024, 40 (05) : 283 - 285
[37] Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults
Letendre, Scott L.
Mills, Anthony
Hagins, Debbie
Swindells, Susan
Felizarta, Franco
Devente, Jerome
Bettacchi, Christopher
Lou, Yu
Ford, Susan
Sutton, Kenneth
Shaik, Jafar Sadik
Crauwels, Herta
D'Amico, Ronald
Patel, Parul
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (03) : 648 - 655
[38] Long-acting cabotegravir plus rilpivirine for HIV treatment: FLAIR week 96 results
Orkin, C.
Oka, S.
Philibert, P.
Brinson, C.
Bassa, A. C.
Gusev, D.
Degen, O.
Gonzalez Garcia, J.
D'Amico, R.
Dorey, D.
Griffith, S.
Margolis, D. A.
St Clair, M.
Williams, P.
Spreen, W. R.
HIV MEDICINE, 2020, 21 : 14 - 14
[39] Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
Johnson, Kamile
Sawkin, Mark T.
DRUGS IN CONTEXT, 2022, 11
[40] Injectable Long-Acting Cabotegravir-Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start
Pinto, Rogerio M.
Hall, Evan
Tomlin, Ryan
JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE, 2023, 34 (02): : 216 - 220

← 1 2 3 4 5 →